Adaptimmune Therapeutics PLC ADAPY
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Revenue compounded at +175.5% a year over the five years to FY2024.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 276 cents this year.
The 11-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.1 | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | −0.1 | −0.1 | −0.2 | 0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | 0.0 |
| EPS, diluted $ | −0.05 | −0.09 | −0.17 | −0.17 | −0.15 | −0.22 | −0.16 | −0.13 | −0.17 | −0.17 | −0.08 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | −275.7 | −187.6 | −115.0 | −57.8 | −56.0 | −74.0 | −42.5 | −38.0 | −43.1 | −16.8 | −392.3 |
| Shares out B | 1.54 | 1.36 | 0.99 | 0.93 | 0.93 | 0.63 | 0.63 | 0.56 | 0.42 | 0.42 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 11 of the 11 fiscal years we could check. 17 checks were skipped: cost of revenue is not tagged before 2024. 14 checks were skipped: the balance sheet is not tagged before 2014. Six checks were skipped: EPS is not tagged before 2013.